Sarepta's eteplirsen gets rare pediatric disease designation

Sarepta Therapeutics Inc. (NASDAQ:SRPT) said FDA granted rare pediatric disease designation to eteplirsen (AVI-4658)

Read the full 144 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE